Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen byRobert Montgomery

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Washington

No Placebo Group

Trial Summary

What is the purpose of this trial?

This pilot clinical trial studies how well degarelix acetate before and during radiation therapy works in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as degarelix acetate, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving degarelix acetate together with radiation therapy may work better in treating prostate cancer.

Research Team

Robert Montgomery

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Eligibility Criteria

Inclusion Criteria

Willing and able to provide written informed consent

Written authorization for use and release of health and research study information has been obtained

Histologically proven adenocarcinoma of the prostate

See 5 more

Treatment Details

Interventions

Degarelix Acetate (Hormone Therapy)
External Beam Radiation Therapy (Radiation)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (degarelix acetate, EBRT)Experimental Treatment3 Interventions

Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.